Nuveen Asset Management, LLC Clovis Oncology, Inc. Transaction History

Nuveen Asset Management, LLC

$345 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.63 - $2.96 $346,054 - $1.63 Million	-549,293 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.43 - $3.14 $269,419 - $591,591	188,405 Added 52.21%	549,293 $32.4 Million
Q4 2021 Feb 14, 2022	BUY	$2.7 - $4.76 $139,036 - $245,116	51,495 Added 16.64%	360,888 $21.3 Million
Q3 2021 Nov 12, 2021	BUY	$4.06 - $5.8 $14,303 - $20,433	3,523 Added 1.15%	309,393 $18.3 Million
Q2 2021 Aug 16, 2021	SELL	$5.02 - $7.05 $520,749 - $731,331	-103,735 Reduced 25.33%	305,870 $18 Million
Q1 2021 May 17, 2021	BUY	$4.81 - $10.34 $54,463 - $117,079	11,323 Added 2.84%	409,605 $24.2 Million
Q4 2020 Feb 16, 2021	BUY	$4.13 - $6.41 $18,275 - $28,364	4,425 Added 1.12%	398,282 $23.5 Million
Q3 2020 Nov 16, 2020	BUY	$4.82 - $7.72 $198,222 - $317,485	41,125 Added 11.66%	393,857 $23.2 Million
Q2 2020 Aug 14, 2020	BUY	$5.69 - $9.69 $27,448 - $46,744	4,824 Added 1.39%	352,732 $20.8 Million
Q1 2020 May 14, 2020	BUY	$3.77 - $11.0 $31,890 - $93,049	8,459 Added 2.49%	347,908 $2.21 Million
Q4 2019 Feb 14, 2020	SELL	$3.0 - $16.43 $225,894 - $1.24 Million	-75,298 Reduced 18.16%	339,449 $3.54 Million
Q3 2019 Nov 14, 2019	BUY	$3.93 - $15.35 $173,065 - $675,967	44,037 Added 11.88%	414,747 $1.63 Million
Q2 2019 Aug 15, 2019	BUY	$12.81 - $25.67 $4.75 Million - $9.52 Million	370,710 New	370,710 $5.51 Million
Q1 2018 May 14, 2018	SELL	$50.12 - $67.72 $614,721 - $830,585	-12,265 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$57.69 - $84.58 $3,749 - $5,497	-65 Reduced 0.53%	12,265 $0
Q3 2017 Nov 14, 2017	BUY	$67.17 - $84.81 $828,206 - $1.05 Million	12,330	12,330 $1.02 Million

Others Institutions Holding CLVS

# of Institutions

Shares Held

166

Call Options Held

Put Options Held

Exane Derivatives

166
Shares

$14
0.0% of portfolio

View Full List

About Clovis Oncology, Inc.

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

More about CLVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.

Account